This week, Sarepta Therapeutics Inc (NASDAQ:SRPT) dosed its first patient with commercial Exondys 51 (eteplirsen), the biotech firm’s intravenous infusion Duchenne muscular dystrophy …
We see Idera’s next generation antisense platform as a driver of future value for the company, says Wedbush
In a research report issued yesterday, Wedbush analyst Heather Behanna reiterated a Buy rating and $6.00 price target on shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA), …
Wedbush analyst Heather Behanna reiterated a Neutral rating on Cubist Pharmaceuticals (NASDAQ:CBST) with a price target of $102, as Hospira (NYSE:HSP) litigation comes to …
Wedbush analyst Heather Behanna maintained a Neutral rating on Cubist Pharmaceuticals (NASDAQ:CBST) and raised his price target to $102 (from $70), following the …
